| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $279,966 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Carter Denise P. | Chief Operating Officer | 1 | $99,991 | 0 | $0 | $99,991 |
| Myers Michael | Chief Executive Officer | 1 | $99,991 | 0 | $0 | $99,991 |
| Lawlor Sally Bridget | Chief Financial Officer | 1 | $49,991 | 0 | $0 | $49,991 |
| Culverwell Anthony James | director | 1 | $29,992 | 0 | $0 | $29,992 |
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Over the last 12 months, insiders at Quoin Pharmaceuticals, Ltd. have bought $279,966 and sold $0 worth of Quoin Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Quoin Pharmaceuticals, Ltd. have bought $364,221 and sold $217 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Carter Denise P. (Chief Operating Officer) — $99,991. Myers Michael (Chief Executive Officer) — $99,991. Lawlor Sally Bridget (Chief Financial Officer) — $49,991.
The last purchase of 6,146 shares for transaction amount of $29,992 was made by Culverwell Anthony James (director) on 2026‑08‑31.
| 2026-08-31 | Culverwell Anthony James | director | 6,146 0.2401% | $4.88 | $29,992 | -24.44% | ||
| 2026-08-31 | Myers Michael | Chief Executive Officer | 20,490 0.8004% | $4.88 | $99,991 | -24.44% | ||
| 2026-08-31 | Carter Denise P. | Chief Operating Officer | 20,490 0.8004% | $4.88 | $99,991 | -24.44% | ||
| 2026-08-31 | Lawlor Sally Bridget | Chief Financial Officer | 10,244 0.4002% | $4.88 | $49,991 | -24.44% | ||
| 2025-10-14 | LANGER DENNIS | director | 15,152 1.5567% | $8.49 | $128,640 | -51.67% | ||
| 2024-12-23 | Myers Michael | Chief Executive Officer | 555,556 9.5152% | $0.45 | $250,000 | -50.47% | ||
| 2024-12-23 | Carter Denise P. | Chief Operating Officer | 555,556 9.5152% | $0.45 | $250,000 | -50.47% | ||
| 2024-12-23 | Dunn Gordon | Chief Financial Officer | 122,221 2.0933% | $0.45 | $54,999 | -50.47% | ||
| 2024-12-23 | Culverwell Anthony James | director | 100,000 1.7127% | $0.45 | $45,000 | -50.47% | ||
| 2024-09-10 | Dunn Gordon | Chief Financial Officer | 20,000 0.5852% | $0.81 | $16,200 | -57.31% | ||
| 2024-09-09 | Dunn Gordon | Chief Financial Officer | 8,856 0.1833% | $0.79 | $7,005 | -68.84% | ||
| 2024-09-09 | Dunn Gordon | Chief Financial Officer | 4,000 0.0838% | $0.80 | $3,200 | -68.84% | ||
| 2024-09-04 | Myers Michael | Chief Executive Officer | 37,094 0.8928% | $0.77 | $28,421 | -62.50% | ||
| 2024-09-04 | Carter Denise P. | Chief Operating Officer | 31,813 0.7825% | $0.78 | $24,912 | -62.50% | ||
| 2024-09-03 | Carter Denise P. | Chief Operating Officer | 5,922 0.1416% | $0.65 | $3,825 | -55.81% | ||
| 2024-09-03 | Myers Michael | Chief Executive Officer | 800 0.0183% | $0.62 | $495 | -55.81% | ||
| 2024-06-07 | Sale | LANGER DENNIS | director | 297 0.008% | $0.73 | $217 | -22.34% |
| Culverwell Anthony James | director | 40364 2.0101% | $158,630.52 | 2 | 0 | <0.0001% |
| Myers Michael | Chief Executive Officer | 37713 1.8781% | $148,212.09 | 4 | 0 | <0.0001% |
| Carter Denise P. | Chief Operating Officer | 37709 1.8779% | $148,196.37 | 4 | 0 | <0.0001% |
| Lawlor Sally Bridget | Chief Financial Officer | 10684 0.5321% | $41,988.12 | 1 | 0 | |
| Dunn Gordon | Chief Financial Officer | 151077 7.5235% | $593,732.61 | 4 | 0 | <0.0001% |
| LANGER DENNIS | director | 15153 0.7546% | $59,551.29 | 1 | 1 | <0.0001% |
$13,664,154 | 40 | -70.35% | $7.05M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
Quoin Pharmaceuticals, Ltd. (QNRX) | $812,698 | 12 | -57.09% | $7.89M |
$4,146,041 | 11 | -40.86% | $8.55M | |
$120,379 | 10 | -24.48% | $7.65M |
| Increased Positions | 18 | +1,800% | 841,336 | +56,389.81% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 14 | New | 838,813 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 19 | +1,800% | 842,828 | +56,389.81% |
| Rhumbline Advisers | $17.00 | <0.01% | 1,210 | -32 | -2.58% | 2025-09-30 |
| Gamma Investing Llc | $4.00 | <0.01% | 278 | +38 | +15.83% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0% | 2 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 1 | -129 | -99.23% | 2025-09-30 |
| Huntington National Bank | $0 | 0% | 1 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $0 | 0% | 0 | -206 | Sold Out | 2025-09-30 |
| Raymond James Financial Inc | $0 | 0% | 0 | -717 | Sold Out | 2025-09-30 |